title: Intralipid Vehicle Does Not Interfere with the Efficacy of Progesterone in Attenuating Edema following Traumatic Brain Injury.
abstract: The recent disappointing results of phase III trials for progesterone (PROG) in traumatic brain injury (TBI) have triggered speculation about reasons for the negative outcomes. One confounding factor may have been the vehicle used to administer PROG. Virtually all of the many pre-clinical experiments informing the clinical trials and reporting beneficial PROG effects used more soluble 2-hydroxypropyl-b-cyclodextrin as a vehicle given intraperitoneally or subcutaneously rather than a lipid formulation given intravenously (IV). The present investigation compared the effect of PROG infusion with that of lipid emulsion (Intralipid®) as a carrier/vehicle on edema following TBI in rats. Eight-mg/kg doses of PROG with 20% Intralipid were given IV via central venous catheter beginning 1 h post-injury over a 1 h duration (1.2 mL/h). Animals were killed and brains removed at 24 h post-injury. All the brain-injured groups showed more edema compared with the control group. However, PROG+Intralipid significantly attenuated cerebral swelling compared with Intralipid alone. No difference was observed between the TBI-alone and Intralipid groups. Although this study used much a smaller volume and shorter duration of Intralipid infusion than the clinical trials (up to 5 days of continuous infusion), our results suggest that the use of Intralipid in rats did not prevent or mask the beneficial effect of PROG.
authors.affiliation: Department of Emergency Medicine, Emory University , Atlanta, Georgia .
authors.forename: Bushra
authors.initials: B
authors.lastname: Wali
authors.affiliation: Department of Emergency Medicine, Emory University , Atlanta, Georgia .
authors.forename: Donald G
authors.initials: DG
authors.lastname: Stein
authors.affiliation: Department of Emergency Medicine, Emory University , Atlanta, Georgia .
authors.forename: Iqbal
authors.initials: I
authors.lastname: Sayeed
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects*; D001929:Brain Edema / Q000188:drug therapy* / Q000209:etiology; D000070642:Brain Injuries, Traumatic / Q000150:complications*; D004195:Disease Models, Animal; D004337:Drug Carriers; D004347:Drug Interactions; D004655:Emulsions / Q000008:administration & dosage; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010743:Phospholipids / Q000008:administration & dosage*; D011374:Progesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013024:Soybean Oil / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D004337:Drug Carriers; D004655:Emulsions; D018696:Neuroprotective Agents; D010743:Phospholipids; C545823:soybean oil, phospholipid emulsion; D011374:Progesterone; D013024:Soybean Oil
keywords: Intralipid; TBI; edema; intravenous; progesterone